Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2014

P&T Committee Updates 


At the December 9, 2013 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed several medications and decided the following.

P&T Committee Review and Decisions

Name

Indication

Decision

Oral Multiple Sclerosis Drugs

Gilenya (fingolimod)

Aubagio (teriflunomide)

Tecfidera (dimethyl fumarate) 

Gilenya, Aubagio, and Tecfidera are medications used to treat multiple sclerosis. They provide oral treatment options for a condition that was previously treated only with injectable medications.

Tecfidera will move to Tier 2
(Tier 3 for
4-Tier formulary).

Continued coverage at Tier 3
(Tier 4 for 4-Tier formulary) for Gilenya and Aubagio.

Linzess (linaclotide)  Linzess is used in adults to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.

Moved to Tier 2
(Tier 3 for 4-Tier formulary)

Eliquis
(apixaban)  
Eliquis is a novel anticoagulant used to reduce the risk of stroke and blood clots in people with atrial fibrillation. Other novel anticoagulants include Pradaxa (dabigatran) and Xarelto (rivaroxaban). Moved  to Tier 2
(Tier 3 for 4-Tier formulary)

 

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Commitment to the Principles of Centered Care

Reminder: Electronic Funds Transfer is Now Available

CLINICIAN CORNER

Update: Aloxi, Anzemet, and Emend Prior Authorization Medial Review Criteria

New Medical Policy: Cell-free Fetal DNA Testing

Medical Policy for Genetic Testing

Reminder: Measures Aimed at Boosting SNF/PCP Care Coordination

P&T Committee Updates

Specialty Pharmacy Updates

Club Drugs: Emerging Trends and Patterns

OFFICE ASSISTANT

2014 Fee Schedule Updates

Update: Gastroenterology Payment Policy

New CMS 1500 Claim Form Now Accepted

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Kristin Edmonston,
Production Coordinator